OPKO Health (NASDAQ:OPK) Trading 5.1% Higher – What’s Next?

OPKO Health, Inc. (NASDAQ:OPK)’s stock price was up 5.1% on Friday . The company traded as high as $1.54 and last traded at $1.5350. Approximately 929,667 shares changed hands during trading, a decline of 65% from the average daily volume of 2,688,704 shares. The stock had previously closed at $1.46.

Analyst Ratings Changes

A number of research analysts recently commented on OPK shares. Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Finally, Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, OPKO Health currently has a consensus rating of “Hold” and an average target price of $1.55.

OPKO Health Stock Performance

The firm has a market cap of $1.11 billion, a P/E ratio of -5.46 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.61. The company’s 50 day moving average is $1.21 and its 200 day moving average is $1.25.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The firm had revenue of $124.20 million for the quarter, compared to analysts’ expectations of $130.51 million. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. The company’s revenue was down 17.1% on a year-over-year basis. As a group, equities analysts predict that OPKO Health, Inc. will post -0.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OPKO Health

A number of institutional investors and hedge funds have recently bought and sold shares of OPK. Bank of America Corp DE raised its position in OPKO Health by 80.0% in the first quarter. Bank of America Corp DE now owns 1,141,849 shares of the biotechnology company’s stock valued at $1,302,000 after purchasing an additional 507,590 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of OPKO Health in the first quarter valued at approximately $125,000. State of Wyoming acquired a new position in shares of OPKO Health in the first quarter valued at approximately $190,000. First Trust Advisors LP bought a new position in OPKO Health in the 1st quarter valued at approximately $570,000. Finally, Fifth Third Bancorp bought a new position in OPKO Health in the 1st quarter valued at approximately $147,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.